NEW YORK and TOKYO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, reported financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 and Recent Operational & Financial Highlights Divested software business subsidiary, HeartCore Co., Ltd (“HeartCore Japan”)Authorized one-time distribution payment to stockholdersAnnounced Go IPO client, rYojbaba Co., Ltd. ...

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, will have senior leadership participating in multiple upcoming investor conferences. The Company will be participating in the virtual Deutsche Bank Lithium and Battery Supply Chain Conference on Thursday, November 20, 2025, and the virtual Bank of America Critical Materials Conference on Monday, November 24, 2025. Add ...

WOOD DALE, Ill. , Nov. 18, 2025 /PRNewswire/ -- AAR CORP. ...

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a joint venture (JV) company agreement with Singapore-based Aiodine Laboratory Pte Ltd. (“Aiodine”) to develop, test and market that company’s novel iodine-based disinfectant solution as a treatment for chronic and acute wounds, and in other c ...

LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, November 22, ...

MIAMI, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) today announced a new initiative with Drinkfinger Enterprises LTD., a groundbreaking fan-experience and beverage-accessory company, to bring next-generation interactive experiences to global sports and entertainment audiences. This collaboration represents a major step forward in uniting physical fan products with real-time digital engagement, unlocking powerful new moments for fans during the world’s most ...

Eightco holds over 10% of the current WLD supply in circulation Introducing Infinity by ORBS, which brings authentication to the enterprise and commercial; with inaugural partners including Coinbase, Kraken and more Infinity by ORBS addresses proof-of-human authentication at scale to wide range of industries including, Finance, Advertising, Gaming, Government The Company is supported by a select group of strategic and institutional investors including: BitMine (BMNR), MOZAYYX, World Foundation, Wedbush, Coi ...

Core Insights - Ethical Web AI has launched AI Vault 2.0, a significant upgrade to its generative AI platform, aimed at enhancing operational and commercial momentum [1][2] Product Features - AI Vault 2.0 includes in-country deployment options to comply with national data sovereignty laws, ensuring sensitive data remains within the chosen jurisdiction [3][4] - The platform now offers Hybrid SaaS access for non-AWS customers, allowing easier adoption while maintaining performance and security through dedicated AWS instances [5] - New roles for Data Protection Officers (DPOs) have been introduced, providing them with clear ownership and control over the deployment and management of AI Vault [6] - Enhanced compliance reporting tools allow DPOs to monitor agent behavior and ensure adherence to data protection regulations [7] - Global access to shared history management enables better oversight and collaboration among teams [8] - The user interface has been significantly upgraded for a more professional and user-friendly experience [9][10] - Both AI Vault and Ethical Web AI websites are being revised to reflect the new capabilities and corporate strategy [11] Strategic Goals - The company aims to prepare for an exit strategy focused on being acquired by a global technology business to scale AI Vault [17][18] - Ethical Web AI is seeking significant new funding to address under-capitalization and enhance organizational capacity for growth [19] - AI Vault 2.0 is designed to unlock new revenue streams through reseller partnerships and the development of a toolkit version, "AI Forge," for large clients [20][21][22] Market Context - AI Vault addresses critical compliance issues faced by enterprises using generative AI products, particularly concerning GDPR and data protection laws [15][16] - The company positions itself as a solution to the barriers preventing responsible AI scaling, emphasizing secure and compliant environments [23]

Irvine, CA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) announced today that it has completed the acquisition of the remaining 49% equity interest in XPLOR Technology Pte. Ltd. (“XPLOR”), the Singapore-based parent company of ONUS Pro, a leading digital asset exchange platform serving Southeast Asia. With 100% ownership of XPLOR and the ONUS Pro ecosystem, the Company believes it now has a solid financial and structural foundation as it continues advancing ...

Core Insights - NetraMark Holdings Inc. has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics for multiple late-stage clinical studies [1][4] - The proprietary NetraAI platform will be utilized to analyze clinical data from these studies, focusing on identifying patient subpopulations that influence treatment and placebo responses [2][3] Group 1: Contract Details - The contracts represent a significant expansion of the ongoing collaboration between NetraMark and the pharmaceutical company, reflecting continued confidence in NetraMark's technology [3][4] - Each study will leverage the NetraAI system, which is designed to identify high-effect-size subgroups within complex datasets, aligning with FDA expectations for explainable AI in clinical development [3][5] Group 2: Technology Overview - NetraAI is engineered to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical data [5][6] - The technology allows for the analysis of smaller datasets while accurately classifying patients based on their sensitivity to drugs and treatment efficacy [6]